Cisplatin resistance and oncogenes--a review

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cisplatin is a widely used chemotherapy drug, but its effectiveness is often limited by cancer cell resistance.
• Mechanisms of cisplatin resistance include reduced drug uptake, increased DNA repair, and altered oncogene expression.
• Oncogenes and transcription factors like ras, c-fos/AP-1, AP-2, and mutated p53 play significant roles in conferring resistance.

Purpose of the Study:

• To review the molecular mechanisms underlying cisplatin resistance in cancer.
• To explore the role of oncogenes and transcription factors in cisplatin resistance.
• To discuss the potential of targeting these molecular factors to overcome resistance and improve cisplatin efficacy.

Main Methods:

• Literature review of studies investigating cisplatin resistance mechanisms.
• Analysis of the role of specific oncogenes (e.g., ras) and transcription factors (e.g., c-fos/AP-1, AP-2, p53) in cisplatin resistance.
• Examination of therapeutic strategies targeting molecular pathways involved in resistance.

Main Results:

• Cisplatin resistance involves multiple pathways, including drug transport, DNA repair, and apoptosis regulation.
• Oncogenes like ras and transcription factors such as c-fos/AP-1, AP-2, and mutated p53 are implicated in cisplatin resistance.
• Mutated p53 influences the expression of genes involved in drug resistance and apoptosis.

Conclusions:

• Understanding the molecular basis of cisplatin resistance is crucial for predicting patient response to therapy.
• Targeting oncogenes and specific molecular pathways involved in resistance, using methods like ribozymes or antisense oligonucleotides, can restore cisplatin sensitivity.
• These targeted strategies hold promise for enhancing cisplatin's efficacy against various malignancies.